

I. AMENDMENTS TO THE CLAIMS

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1. (currently amended) A solid oral dosage form, comprising a combination of an opioid agonist and naltrexone or a pharmaceutically acceptable salt thereof; wherein the combination is orally therapeutically effective for the treatment of pain and is selected from the group consisting of:

naltrexone or a pharmaceutically acceptable salt thereof and hydrocodone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.03:1 to about 0.27:1;

naltrexone or a pharmaceutically acceptable salt thereof and oxycodone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.037:1 to about 0.296:1;

~~naltrexone or a pharmaceutically acceptable salt thereof and codeine or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.005:1 to about 0.044:1;~~

naltrexone or a pharmaceutically acceptable salt thereof and hydromorphone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.148:1 to about 1.185:1;

naltrexone or a pharmaceutically acceptable salt thereof and levorphanol or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.278:1 to about 2.222:1;

~~naltrexone or a pharmaceutically acceptable salt thereof and meperidine or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.0037:1 to about 0.0296:1; and~~

naltrexone or a pharmaceutically acceptable salt thereof and morphine or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.018:1 to about 0.148:1.

Claim 2. (cancelled)

Claim 3. (previously presented) The oral dosage form of claim 1, wherein the opioid agonist is hydrocodone or a pharmaceutically acceptable salt thereof.

Claim 4. (cancelled)

Claim 5. (previously presented) The oral dosage form of claim 3, wherein the ratio of naltrexone or pharmaceutically acceptable salt thereof to hydrocodone or pharmaceutically acceptable salt thereof is from about 0.05:1 to about 0.20:1.

Claim 6. (cancelled)

Claim 7. (original) The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from the group consisting of an NSAID, a COX-2 inhibitor, acetaminophen, aspirin, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, an antitussive, an expectorant, a decongestant, an antihistamine and mixtures thereof.

Claim 8. (original) The oral dosage form of claim 1, further comprising one or more pharmaceutically acceptable inert excipients.

Claim 9. (cancelled)

Claim 10. (previously presented) The oral dosage form of claim 1, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 11. (original) The oral dosage form of claim 1, further comprising a sustained release carrier which imparts sustained release properties to said opioid agonist.

Claim 12. (previously presented) The oral dosage form of claim 1, wherein said opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof.

Claim 13. (cancelled)

Claim 14. (previously presented) The oral dosage form of claim 1, wherein said opioid agonist is hydromorphone or a pharmaceutically acceptable salt thereof.

Claim 15. (previously presented) The oral dosage form of claim 1, wherein said opioid agonist is levorphanol or a pharmaceutically acceptable salt thereof.

Claim 16-17. (cancelled)

Claim 18. (previously presented) The oral dosage form of claim 1, wherein said opioid agonist is morphine or a pharmaceutically acceptable salt thereof.

Claim 19. (previously presented) The oral dosage form of claim 1, wherein said opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof, and the weight ratio of naltrexone or pharmaceutically acceptable salt thereof to oxycodone or pharmaceutically acceptable salt thereof is from about 0.056:1 to about 0.222:1.

Claims 20 - 35 (cancelled).

Claim 36. (previously presented) The oral dosage form of claim 3, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 37. (previously presented) The oral dosage form of claim 12, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 38. (cancelled)

Claim 39. (previously presented) The oral dosage form of claim 14, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 40. (previously presented) The oral dosage form of claim 15, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claims 41-42. (cancelled)

Claim 43. (previously presented) The oral dosage form of claim 18, wherein said naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 44. (previously presented) The oral dosage form of claim 3, wherein the opioid agonist is hydrocodone bitartrate.

Claims 45-51. (cancelled)

Claim 52. (previously presented) The oral dosage form of claim 14, wherein the weight ratio of naltrexone or pharmaceutically acceptable salt thereof to hydromorphone or pharmaceutically acceptable salt thereof is from about 0.222:1 to about 0.889:1.

Claim 53. (previously presented) The oral dosage form of claim 15, wherein the weight ratio of naltrexone or pharmaceutically acceptable salt thereof to levorphanol or pharmaceutically acceptable salt thereof is from about 0.417:1 to about 1.667:1.

Claims 54-55. (cancelled)

Claim 56. (previously presented) The oral dosage form of claim 18, wherein the weight ratio of naltrexone or pharmaceutically acceptable salt thereof to morphine or pharmaceutically acceptable salt thereof is from about 0.028:1 to about 0.111:1.